Effects of a late add-on therapy of pegylated interferon (peg-IFNA) to ongoing nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB).

Trial Profile

Effects of a late add-on therapy of pegylated interferon (peg-IFNA) to ongoing nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top